microRNA (miRNA)

Global Market Trajectory & Analytics

MCP13362

EXECUTIVE ENGAGEMENTS

POOL

2994
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

539
Interactions with Platform & by Email

PARTICIPANTS

92
Unique # Participated

VALIDATIONS

26
Responses Validated*

COMPANIES

42
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

156

PAGES

228

EDITION

9

PRICE

USD 4950

CODE

MCP13362


COMPETITIVE METRICS

COMPANY

D S N T

% *

20Med Therapeutics

Abcam PLC

AceRNA

Agilent Technologies, Inc.

AKESOgen, Inc.

AptamiR Therapeutics

ARTHEx Biotech

Biodynamics Laboratory Inc.

Bio-Genex Laboratories

Bio-Rad Laboratories, Inc.

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for microRNA (miRNA) estimated at US$225.5 Million in the year 2020, is projected to reach a revised size of US$556.1 Million by 2027, growing at aCAGR of 13.8% over the period 2020-2027. Products, one of the segments analyzed in the report, is projected to record 12.2% CAGR and reach US$290.1 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Services segment is readjusted to a revised 15.7% CAGR for the next 7-year period.
The microRNA (miRNA) market in the U.S. is estimated at US$97 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$60 Million by the year 2027 trailing a CAGR of 17.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.1% and 13% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR.

SELECT PLAYERS

Abcam PLC; Agilent Technologies, Inc.; Bioline GmbH; Bio-Rad Laboratories, Inc.; BioVendor - Laboratorni medicina a.s; Dharmacon, Inc.; F. Hoffmann-La Roche AG; GeneCopoeia, Inc.; HTG Molecular Diagnostics, Inc.; Illumina, Inc.; Kaneka Eurogentec SA; MilliporeSigma; Miltenyi Biotec GmbH; Nanostring Technologies, Inc.; New England Biolabs, Inc.; Promega Corporation; Qiagen NV; Rosetta Genomics Ltd.; System Biosciences, Inc.; Thermo Fisher Scientific, Inc.

SEGMENTS

» Type (Products, Services) » Application (Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases, Other Applications) » End-Use (Academic & Government Research Institutes, Biotech & Pharma Companies, Other End-Uses)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
A Prelude to MicroRNA
Impact of Covid-19 and a Looming Global Recession
2020 Marked as a Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021
EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
COVID-19 Impact on mRNA Market
Global Market Prospects and Outlook
Global miRNA Market Set to Witness Rapid Growth
Disease Diagnostics Segment Leads the Market
MicroRNAs Likely to Be Instrumental in Disease Diagnosis and Treatment
Polymerase Chain Reaction (PCR) Dominates the Instruments Category
Academic and Government Research Institutes Holds the Largest Share
North America Dominates Global miRNA Market, Asia-Pacific to Witness Steady Growth
Competition
Increasing Emphasis on R&D by Players to Boost Market Growth
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Incidence of Infectious Diseases and Chronic Conditions to Help miRNA Market Gallop Ahead
EXHIBIT: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
Increasing Application in Cancer Diagnostics as Biomarkers to Drive Market Growth
EXHIBIT: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 4: Breakdown of Total Number of Cancer Cases by Region: 2020
EXHIBIT: Breakdown of Total Number of Cancer Cases by Type: 2020
The Future of miRNA-based Cancer Biomarkers
Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth
EXHIBIT 5: Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
EXHIBIT: Infection Rates of Viruses ((per infected person)) Involved in Outbreaks Worldwide: 2020
EXHIBIT 10: Infectious Diseases Related Mortality High Among Children below 5 Years: Breakdown of Leading Causes of Death in Children below 5 Years (in %)
MicroRNA Biomarkers Hold Promise for Diagnosis of Infectious Diseases
Focus on Development of miRNA-based Therapeutics Bodes Well for Market Growth
Increasing Investments in miRNA to Bolster Market Growth
Diagnostics and Therapeutics Investments
Standard Methods Utilized to measure miRNA Biomarkers
Advancements in Detection Methodologies Focus on Enhancing Sensitivity and Selectivity of miRNA Detection
Increasing Demand for Liquid Biopsies to Drive the MicroRNA Market
miRNA by Type of Gastrointestinal Cancers
Circulating miRNAs as Cancer Detectors
Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market
EXHIBIT 12: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
Growing Global Healthcare Spending and Supportive Government Initiatives Boost Market Prospects
EXHIBIT 6: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
EXHIBIT 9: Per Capita Healthcare Expenditure (in $) by Select Countries for 2018
miRNA and Next Generation Sequencing
Market Restraints
AN INSIGHT INTO MIRNA APPLICATIONS
CANCER
Role of miRNA in Cancer Cell
HEART DISEASE
miRNA-712
Human Homolog—microRNA-205
KIDNEY DISEASE
NERVOUS SYSTEM
Stroke
ALCOHOLISM
OBESITY
HEMOSTASIS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for microRNA (miRNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for microRNA (miRNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
World 11-Year Perspective for microRNA (miRNA) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2016, 2021 & 2027
World Current & Future Analysis for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
World 11-Year Perspective for Products by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
World Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
World 11-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
World 11-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
World Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
World 11-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
World Current & Future Analysis for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
World 11-Year Perspective for Immunological Disorders by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
World Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
World 11-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
World Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
World 11-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
World 11-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
World Current & Future Analysis for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
World 11-Year Perspective for Academic & Government Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
World Current & Future Analysis for Biotech & Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Biotech & Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
World 11-Year Perspective for Biotech & Pharma Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
World 11-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
UNITED STATES
USA Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
USA 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
USA Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
USA 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
USA Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
USA 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
CANADA
Canada Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Canada 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
Canada Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Canada 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
Canada Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Canada 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
JAPAN
Japan Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Japan 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
Japan Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Japan 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
Japan Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Japan 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
CHINA
China Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
China 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
China Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
China 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
China Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
China 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
EUROPE
Europe Current & Future Analysis for microRNA (miRNA) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for microRNA (miRNA) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Europe 11-Year Perspective for microRNA (miRNA) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2016, 2021 & 2027
Europe Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Europe 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
Europe Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Europe 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
Europe Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Europe 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
FRANCE
France Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
France 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
France Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
France 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
France Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
France 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
GERMANY
Germany Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Germany 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
Germany Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Germany 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
Germany Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Germany 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
ITALY
Italy Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Italy 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
Italy Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Italy 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
Italy Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Italy 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
UNITED KINGDOM
UK Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
UK 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
UK Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
UK 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
UK Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
UK 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Rest of Europe 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
Rest of Europe Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Rest of Europe 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
Rest of Europe Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Rest of Europe 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Asia-Pacific 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
Asia-Pacific Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Asia-Pacific 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
Asia-Pacific Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Asia-Pacific 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Rest of World 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
Rest of World Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Rest of World 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
Rest of World Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
Rest of World 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
Total Companies Profiled: 42

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com